drugset / Trial / NCT00987727

Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye

NCT00987727

Phase 4 Completed 82 enrolled Allergan
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.

Timeline

Start
2009-11
Primary completion
2010-07
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboxymethylcellulose Other / unclassified 0.5 %
Subject Glycerin Other / unclassified 0.9 %
Comparator Sodium Hyaluronate Other / unclassified 0.18 %

Indications